{"nctId":"NCT02042183","briefTitle":"Lubiprostone in Children With Functional Constipation","startDateStruct":{"date":"2013-12-13","type":"ACTUAL"},"conditions":["Constipation - Functional"],"count":606,"armGroups":[{"label":"Lubiprostone","type":"EXPERIMENTAL","interventionNames":["Drug: Lubiprostone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Lubiprostone","otherNames":["Amitiza"]},{"name":"Placebo","otherNames":["Matching Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Medically-confirmed diagnosis of Functional Constipation per Rome III Diagnostic Criteria for Childhood Functional Constipation\n* At least 6 years of age but less than 18 years of age at the time of randomisation\n* Only stable dose of selective serotonin re-uptake inhibitors (SSRIs), serotonin-specific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO) inhibitors are allowed if subject is taking antidepressants\n\nExclusion Criteria:\n\n* Any gastrointestinal (GI) condition, other than constipation and/or irritable bowel syndrome (IBS), affecting GI motility or defecation\n* Untreated faecal impaction at the time of screening\n* Medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Classified as Overall Responders at Week 12","description":"An overall responder is defined as a participant who qualified as a weekly responder for 9 of the 12 treatment weeks, with durability demonstrated by at least 3 of the responder weeks occurring during the last 4 weeks of the treatment period. A weekly responder is defined as a participant who has at least 3 spontaneous bowel movements during the week, and at least one more than at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Number of SBMs Observed Each Week for 12 Weeks","description":"Data provided is based on observed cases. Baseline is the average of the 2 weeks before being randomized. Participants are summarized by actual dose received after week 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.836"},{"groupId":"OG001","value":"1.42","spread":"0.855"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"2.137"},{"groupId":"OG001","value":"2.50","spread":"2.117"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":"2.422"},{"groupId":"OG001","value":"2.69","spread":"2.328"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":"2.446"},{"groupId":"OG001","value":"2.59","spread":"2.435"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.94","spread":"2.531"},{"groupId":"OG001","value":"2.69","spread":"2.499"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":"2.498"},{"groupId":"OG001","value":"2.68","spread":"2.495"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":"2.454"},{"groupId":"OG001","value":"2.65","spread":"2.163"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":"2.483"},{"groupId":"OG001","value":"2.75","spread":"2.704"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.94","spread":"2.501"},{"groupId":"OG001","value":"2.64","spread":"2.444"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.83","spread":"2.286"},{"groupId":"OG001","value":"2.37","spread":"1.875"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":"2.326"},{"groupId":"OG001","value":"2.40","spread":"2.103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":"2.251"},{"groupId":"OG001","value":"2.60","spread":"2.362"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":"2.497"},{"groupId":"OG001","value":"2.75","spread":"2.530"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":400},"commonTop":["Nausea","Abdominal pain","Vomiting","Headache","Diarrhoea"]}}}